Newsroom

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Teachers Insurance and Annuity Association of America/Teachers Advisors, LLC/ Nuveen Asset Management, LLC (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest Nasdaq-100 Moderate Buffer UCITS ETF - December 24.07.2026 QDEC.LN IE000GAKWFA7  550,002.00 USD  13,239,784.83   24.072  ...

SAN FRANCISCO, Kalifornien, USA--(BUSINESS WIRE)--LTM, Business Creativity-Partner für die weltweit größten Unternehmen, gab heute eine strategische Partnerschaft mit Cognition bekannt, dem KI-Labor hinter dem Software Engineering-Agenten Devin. Im Rahmen dieser Partnerschaft hat LTM Devin, den autonomen KI-Ingenieur von Cognition, in BlueVerse TM RightLogic integriert. LTM BlueVerse RightLogic ist ein Framework für die Bewertung von Cybersicherheit und die Absicherung von Risiken, das Unterneh...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest Nasdaq-100® Moderate Buffer UCITS ETF - March 24.07.2026 QMAR.LN IE0006S0EBF2   50,002.00 USD   1,230,568.64   24.610  ...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Charles Schwab Investment Management, Inc. (CSIM) in its capacity as investment advisor to clients. CSIM expressly disclaims beneficial ownership of the shares described in this form 8.3. (b) Owner or controller of interests and short positions...

NEWARK, Californie et BANGALORE, Inde--(BUSINESS WIRE)--Ohmium International Inc., l’un des principaux fabricants d’électrolyseurs modulaires de pointe à membrane échangeuse de protons (PEM) à haut rendement, a annoncé aujourd’hui la nomination de Mark Griffin au poste de directeur commercial (CCO). M. Griffin dirigera l’organisation des ventes et du marketing d’Ohmium, avec pour mission de stimuler la croissance du chiffre d’affaires, l’acquisition de clients et l’expansion d’un écosystème mon...

CHICAGO & LUXEMBURG--(BUSINESS WIRE)--Northern Trust (Nasdaq: NTRS) maakt vandaag bekend dat het is geselecteerd om bepaalde fondsadministratiediensten en andere aanverwante diensten te verlenen aan Dawson Partners. Dawson Partners is een wereldwijde alternatieve beleggingsbeheerder die zich richt op het aanbieden van gestructureerde oplossingen voor particuliere markten. Het bedrijf, met hoofdkantoor in Toronto en vestigingen in Londen, New York en Hongkong, beheert meer dan 27 miljard Amerika...

CHICAGO et LUXEMBOURG--(BUSINESS WIRE)--Northern Trust (Nasdaq : NTRS) a annoncé aujourd’hui avoir été sélectionné pour fournir certains services d’administration de fonds et d’autres services connexes à Dawson Partners. Dawson Partners est un gestionnaire mondial d’actifs alternatifs qui se concentre sur la fourniture de solutions structurées aux marchés privés. Basée à Toronto et disposant de bureaux à Londres, New York et Hong Kong, la société gère plus de 27 milliards USD d’actifs (au 31 ma...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--LAPIX Therapeutics has appointed Abbas Kazimi, Chief Executive Officer of Nimbus Therapeutics, to its Board of Directors as the Company advances its TIM 3/4 agonist program through Phase 1b clinical trials in rheumatoid arthritis (RA) and atopic dermatitis (AD). Kazimi brings more than two decades of biotechnology leadership experience spanning company building, corporate strategy, financing, and drug development. As CEO of Nimbus Therapeutics, he has overseen...

BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, a global leader in artificial intelligence-driven solutions for oncology, clinical trial matching, and patient navigation, and the Latin American Study Group on Lymphoproliferative Disorders (GELL), one of the most influential scientific and academic networks dedicated to lymphomas and hematologic malignancies in Latin America, today announced a strategic partnership focused on advancing clinical research, physician education, and innovation throu...